REFERENCES
(1)Muggia, F. Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol. Oncol. 2009, 112, 275–281.
(2)Rozencweig, M.; Von Hoff, D. D.; Slavik, M.; Muggia, F. M. Cis-diamminedichloroplatinum(II): a new anticancer drug. Ann. Intern. Med. 1977, 86, 803–812.
(3)Bosl, G. J.; Motzer, R. J. Medical progress: testicular germ-cell cancer. N. Engl. J. Med. 1997, 337, 242–254.
(4)Lippard, S. J.; Pil, P. Encyclopedia of Cancer, cis2platin and Related Drugs. San Diego, California: Academic Press 1997.
(5)Screnci, D.; McKeage, M. J. Platinum neurotoxicity: clinical profiles, experimental models and neuroprotective approaches. Inorg. Biochem. Inorg. Biochem. 1999, 77, 105–110.
(6)Daugaard, G.; Abildgaard, U. Cisplatin nephrotoxicity. Cancer Chemother. Pharmacol. 1989, 25, 1–9.
(7)Cvitkovic, E. Cumulative toxicities from cisplatin therapy and current cytoprotective measures. Cancer Treat. Rev. 1998, 24, 265–281.
(8)Abu-Surrah, A. S.; Al-Sa΄doni, H. H.; Abdalla, M. Y. Palladium-based chemotherapeutic agents: routes toward complexes with good antitumor activity. Cancer Ther. 2008, 6, 1–10.
(9)Caires, A. C. F. Recent advances involving palladium(II) complexes for the cancer therapy. Anticancer. Agents. Med. Chem. 2007, 7, 484–491.
(10)Serrano, F. A.; Matsuo, A. L.; Monteforte, P. T.; Bechara, A.; Smaili, S. S.; Santana, D. P.; Rodrigues, T.; Pereira, F. V.; Silva, L. S.; Machado, J. Jr.; Santos, E. L.; Pesquero, J. B.; Martins, R. M.; Travassos, L. R.; Caires, A. C.; Rodrigues, E. G. A cyclopalladated complex interacts with mitochondrial membrane thiol-groups and induces the apoptotic intrinsic pathway in murine and cisplatin-resistant human tumor cells. BMC Cancer. 2011, 11, 296–311.
(11)Sun, Y. G.; Sun, D.; Yu, W.; Zhu, M. C.; Ding, F.; Liu, Y. N.; Gao, E. J.; Wang, S. J.; Xiong, G.; Dragutan, I.; Dragutan, V. Synthesis, characterization, interaction with DNA and cytotoxicity of Pd(II) and Pt(II) complexes containing pyridine carboxylic acid ligands. Dalton Trans. 2013, 42, 3957–3967.
(12)Wang, P. P.; Wang, Y. J.; Lin, Q. Y.; Shen, L. L.; Zhao, Y. L. Synthesis, crystal structure and bioactivity of a Pd(II) complex with demethylcantharate and 2,2΄-bipyridine. Chin. J. Struct. Chem. 2012, 31, 1175–1181.
(13)Jamieson, E. R.; Lippard, S. J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 1999, 99, 2467–2498.
(14)Todd, R. C. Structure of duplex DNA containing the cisplatin 1,2-{Pt(NH3)2}2+-d(GpG) cross-link at 1.77 Å resolution. J. Inorg. Biochem. 2010, 104, 902–908.
(15)Ang, W. H.; Myint, M. Transcription inhibition by platinum-DNA cross-links in live mammalian cells. J. Am. Chem. Soc. 2010, 132, 7429–7435.
(16)Zhang, M. J.; Yuan, X. H.; Ma, L.; Zhao, J. Y.; Gao, L. X. Selective deprotection of N-Boc catalyzed by silica Gel. Chem. Res. Chin. Univ. 2007, 28, 2330–2332.
(17)Guneya, S.; Yilmaza, V. T.; Harrison, W. T. Synthesis, crystal structure and properties of trans-[Cu(sac)2(en)2] (sac = saccharinato and en = ethylenediamine). J. Coord. Chem. 2006, 59, 1123–1130.
(18)Lepecq, J. B.; Paoletti, C. A fluorescent complex between ethidium bromide and nucleic acids. Physieal-chemieal characterization. J. Mol. Biol. 1967, 27, 87–106.
(19)Sheldrick, G. M. A short history of SHELX. Acta Cryst. 2008, A64, 112–122.
(20)Wolf, A.; Shimer, Jr. G. H.; Meehan, T. Polycyclic aromatic hydrocarbons physically intercalate into duplex regions of denatured DNA. Biochemistry 1987, 26, 6392–6396.
(21)Yi, H. B.; Lee, H. M.; Kim, K. S. Interaction of benzene with transition metal cations: theoretical study of structures, energies, and IR spectra. J. Chem. Theory. Comput. 2009, 5, 1709–1717.
(22)Lakowicz, J. R.; Webber, G. Quenching of fluorescence by oxygen. A probe for structural fluctuations in macromolecules. Biochemistry 1973, 12, 4161–4170. |